David A. Siegel Xenon Pharmaceuticals Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 298,700 shares of XENE stock, worth $10.2 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
298,700
Previous 273,700
9.13%
Holding current value
$10.2 Million
Previous $10.8 Million
8.72%
% of portfolio
0.03%
Previous 0.03%
Shares
23 transactions
Others Institutions Holding XENE
# of Institutions
219Shares Held
70.4MCall Options Held
109KPut Options Held
2.1K-
Avoro Capital Advisors LLC New York, NY5.67MShares$194 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$155 Million1.73% of portfolio
-
Wellington Management Group LLP Boston, MA3.78MShares$129 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$99.9 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$98.2 Million0.06% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.13B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...